Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Reversal of rocuronium-induced neuromuscular block by the combination of low-doses of
neostigmine plus sugammadex decreases the cost of anesthetic medications, while maintaining
efficacy of reversal in obese patients.
Phase:
Early Phase 1
Details
Lead Sponsor:
Iuliu Hatieganu University of Medicine and Pharmacy